Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima–media thickness

Background The European Lacidipine Study on Atherosclerosis (ELSA) randomized 2334 hypertensive patients to either the lipophilic calcium antagonist lacidipine or the β-blocker atenolol for 4 years. About 35% of subjects in both groups received additional hydrochlorothiazide (12.5–25 mg/day). The patients were followed up for carotid intima–media thickness (IMT) changes for 3.7 years. Objectives The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment. Methods At baseline 2034 patients had, in addition to blood pressure (BP), measurements of blood glucose, serum high-density lipoprotein (HDL)-cholesterol, triglycerides and body mass index (BMI > 28.8 for men and > 26.2 for women were taken to correspond to waist circumference > 102 and > 88 cm, respectively). These measurements were repeated after 4 years of treatment in 1444 patients. MS was defined according to Adults Treatment Panel III (ATP III). Results A high proportion of ELSA patients (33.3%) had MS at baseline, with no difference between atenolol and lacidipine. Baseline IMT was slightly greater in MS patients, but only the difference in mean maximum IMT at common carotids and bifurcations (CBMmax) achieved significance (P = 0.0325). Progression of CBMmax was also slightly greater in MS patients (P = 0.0241), but significance was lost when adjusted for covariates. No significant difference was found in the incidence of new cardiovascular events between patients with and without MS. The incidence of new MS was 21.4%, and significantly greater in patients under atenolol (25.2%) than lacidipine (17.7%; P = 0.0045). New-onset diabetes occurred in 5.54% of ELSA patients, and was three times higher among patients with than those without MS (10.28 versus 3.43%, P > 0.0001). Conclusions Our analyses show a high prevalence of MS in ELSA hypertensives, a substantial incidence of new cases of MS and diabetes, the latter mostly among patients with MS. These analyses also show that in ELSA lacidipine was superior to atenolol, not only in showing a lower progression of carotid atherosclerosis, but also in causing a significantly lower incidence of new MS.

[1]  G. Mancia,et al.  Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study: Daily Life Blood Pressure, Cardiac Damage, and Prognosis , 2007, Hypertension.

[2]  G. Mancia,et al.  New-onset diabetes and antihypertensive drugs. , 2006, Journal of hypertension.

[3]  L. Bouter,et al.  Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study , 2005, Circulation.

[4]  E. Ford,et al.  Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. , 2005, Atherosclerosis.

[5]  G. Leoncini,et al.  Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients , 2005, Journal of internal medicine.

[6]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[7]  P. Whelton,et al.  Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). , 2004, Annals of epidemiology.

[8]  F. Magrini,et al.  Metabolic syndrome and target organ damage in untreated essential hypertensives , 2004, Journal of hypertension.

[9]  Ken Williams,et al.  National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.

[10]  Nathan D. Wong,et al.  Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.

[11]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[12]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[13]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[14]  G. Mancia,et al.  Absolute and relative changes in carotid intima–media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA) , 2004, Journal of hypertension.

[15]  J. Tuomilehto,et al.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.

[16]  E. Mannarino,et al.  Prognostic value of the metabolic syndrome in essential hypertension. , 2004, Journal of the American College of Cardiology.

[17]  E. Jeffrey Metter,et al.  Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness , 2004 .

[18]  Latha Palaniappan,et al.  Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. , 2004, Diabetes care.

[19]  Jing Chen,et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.

[20]  B. Howard,et al.  Cardiovascular risk associated with the metabolic syndrome , 2004, Current diabetes reports.

[21]  P. Wilson,et al.  Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. , 2004, Diabetes care.

[22]  Reubin Andres,et al.  Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. , 2003, Journal of the American College of Cardiology.

[23]  B. Howard,et al.  Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). , 2004, The American journal of cardiology.

[24]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[25]  M. Carnethon,et al.  Association between microalbuminuria and the metabolic syndrome: NHANES III. , 2003, American journal of hypertension.

[26]  L. Lindholm,et al.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) , 2003, Journal of hypertension.

[27]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[28]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[29]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[30]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[31]  P. Nilsson,et al.  Insulin resistance in non‐diabetic subjects is associated with increased incidence of myocardial infarction and death , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[32]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[33]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[34]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[35]  B. Fagerberg,et al.  The Metabolic Syndrome, LDL Particle Size, and Atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) Study , 2000, Arteriosclerosis, thrombosis, and vascular biology.